TEL AVIV, Israel – GemmaCert, a provider of dependable solutions for cannabis analysis, has released outcomes for 2020 under its worldwide initiative that is analytical map cannabis strength worldwide and evaluate the accuracy of advertised cannabis potency based on actual results. In 2020, GemmaCert accumulated over 1.5 million potency scans in 35 countries on 6 continents.
According to the company that is israeli the global THC average in THC-dominant plants tested on GemmaCert products in regulated areas in 2020 had been 15.35%. For CBD in CBD flowers that are dominant it was 8.90%. Dry flowers form the product category that is largest within the cannabis market. In accordance with BDS Analytics, flowers comprised 45% of U.S. cannabis sales that are retail 2020.
GemmaCert flower potency data for key markets included:
|Flowers||USA||Canada||The Netherlands||South Africa||Australia||Israel|
Meanwhile, A study that is recent the University of new york and Wake Forest University unearthed that many cannabis flower items marketed online by dispensaries over the united states of america claimed THC amounts above 15%. This follows a youthful research in Washington state which revealed that items with labels claiming THC quantities of 15% or more accounted for over 90% of product sales. Unsurprisingly, the cost of cannabis rises with increasing levels of THC.
The GemmaCert information confirms that real THC effectiveness amounts take normal above 15% for THC flowers that are dominant. However, the data also indicates that a meaningful share of flowers are mislabelled with THC values higher than actual:
|THC Dominant Flowers||World||USA||Canada||Netherlands||South Africa||Australia||Israel|
|% of flowers with THC < 15%||45%||30%||37%||41%||64%||37%||38%|
Therefore, consumers need to be aware that there is a reasonable chance they are overpaying for these goods. Inaccurate labelling remains a problem that is common the cannabis industry. “Cannabis organizations need certainly to do far more to make sure their labels are accurate. Otherwise, customer trust will erode, and brands will eventually lose value,” said Dr. Setton.
“GemmaCert’s solutions for cannabis empower that is testing to carry out rigorous, timely, affordable, and reliable in-house testing so that they can continuously verify label accuracy,” Dr. Setton added.
GemmaCert was founded in 2015 in collaboration with the Hebrew University of Jerusalem. GemmaCert devices are carefully tested and hand-assembled in Israel before delivered around the world. Devices are TÜV Rheinland certified, CE compliant, conform with European and German Pharmacopeia, and satisfy privacy that is necessary data security requirements. R&D is conducted at the company’s ISO 17025 laboratory that is certified to cannabis diagnostics under permit by the Israel Ministry of wellness. GemmaCert owns the world’s reference database that is largest of cannabis spectra sourced from around the world through the years. www.gemmacert.com